DOCS - Doximity, Inc.
The market seems concerned that AI could replace some of Doximity's solutions for the medical community. However, its powerful ecosystem, paired with complex regulations, shouldn't be easily disrupted.
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced that Jeff Tangney, co-founder and CEO, will present at the William Blair 46th Annual Growth Stock Conference on Tuesday, June 2, 2026 at 4:40 p.m. Central Time. About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include more than 85% of U.S. physicians across all specialties a.
OptimizeRx expands DSP integration to unlock scalable EHR ad campaigns and boost inventory use despite lowering 2026 revenue guidance.
Dr Martens PLC (LSE:DOCS) returned to profit growth last year as the bootmaker tightened discounting, improved margins and pushed ahead with a turnaround centred on higher-quality sales. The FTSE 250-listed group reported an adjusted pre-tax profit of £55 million in the year to 29 March, up 61% on the year before, while revenue fell 2.9% to £764.9 million.
Hims & Hers (NYSE:HIMS) is dominating headlines this week because the GLP-1 darling just delivered one of the ugliest quarters in the telehealth sector's short history, and bargain hunters are circling the wreckage.
Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing.
Investors interested in stocks from the Medical Info Systems sector have probably already heard of Doximity (DOCS) and Hims & Hers Health, Inc. (HIMS). But which of these two companies is the best option for those looking for undervalued stocks?
Doximity teams with Aledade to bring AI-powered documentation and clinical search tools into physician workflows and value-based care settings.
Doximity, Inc. delivered mixed FY26 results, with solid revenue growth but margin compression and a cautious near-term outlook. AI-driven engagement is accelerating, with rapid adoption of clinical tools and strong enterprise traction, but monetisation lags due to regulatory and operational friction. FY27 is positioned as a transition year, with guidance for just 4% revenue growth and EBITDA margin compression as AI investments ramp.
Doximity (DOCS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Pre-Market Stock Futures: Futures are trading sharply lower as we get set to end one of the most exciting weeks on Wall Street in 25 years. Positive meetings in China with President Trump, who brought his CEO contingent and Elon Musk, and President Xi, massive upside earnings and forward guidance from an OG tech and... Here Are Friday's Top Wall Street Analyst Research Calls: Arista Networks, BWX Technologies, Cisco Systems, Danaher, Doximity, Estee Lauder, Illumina, Texas Roadhouse, Workday, and More
DOCS' revenues top estimates as AI tool adoption and large customer growth fuel engagement despite weaker earnings and margin pressure.
Doximity Inc. (NYSE:DOCS) shares are down on Thursday after the company reported mixed results for the fourth quarter and issued soft annual guidance.
Stock futures are higher Thursday, putting the S&P 500 and Nasdaq on track for more record highs; President Trump and Chinese President Xi Jinping are through their first private meeting, where they reportedly discussed trade, Iran and Taiwan; Cisco shares are soaring in premarket trading after the networking equipment maker reported better-than-expected results and announced layoff plans to invest in AI; the market's appetite for new AI stocks will be tested today as AI chipmaker Cerebras is set to make its trading debut; and shares of Doximity are plunging after the medical networking platform missed profit and outlook estimates. Here's what you need to know today.
Doximity Inc (NYSE:DOCS) on Wednesday reported mixed fourth-quarter financial results and issued weak first-quarter sales guidance.
Shares of Doximity (NYSE: DOCS) plunged on Thursday after the telehealth platform reported weaker-than-expected quarterly profit and issued fiscal 2027 revenue guidance that fell significantly short of Wall Street estimates. The figures intensified investor concerns about slowing growth and rising spending tied to artificial intelligence initiatives.
Doximity, Inc. (DOCS) Q4 2026 Earnings Call Transcript
Doximity NYSE: DOCS reported fiscal fourth-quarter revenue above the high end of its guidance and said it is entering what management called an “AI investment year,” with higher spending planned for artificial intelligence products even as near-term growth in the digital pharma advertising market remains soft.
Doximity (DOCS) came out with quarterly earnings of $0.26 per share, missing the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.38 per share a year ago.